News

American Oncology Network, LLC announced today Brad Prechtl’s retirement as President and Chief Development Officer effective January 1, 2023.

In a retrospective study, investigators assessed the risk of development a malignancy in patients with psoriasis. Findings showed that select patients with psoriasis have a higher risk cancer risk.

VIKTORIA-1 is a phase 3 study evaluating treatment with gedatolisib plus fulvestrant with or without palbociclib in patients with HR-positive, HER-negative breast cancer.

Florida Cancer Specialists & Research Institute participated in the phase 3 POSEIDON, which led to FDA approval of a new immunotherapy that improves chemotherapy treatment for metastatic non small cell lung cancer.

Florida Cancer Specialists & Research Institute, welcomes Robert Ferdman, MD to the statewide practice.

In an interview with Targeted Oncology, Jay W. Granzow, MD, discussed the diagnosis and early detection of patients with cancer-related secondary lymphedema.

Following impressive data presented at the ASH Annual Meeting, the FDA granted approval to olutasidenib or the treatment of patients with treatment-naïve and relapsed or refractory acute myeloid leukemia.

In an interview with Targeted Oncology, Channing J. Paller, MD, discussed the current approaches to radiation therapy, androgen deprivation therapy, and molecular imaging for men with prostate cancer who have biochemical recurrence.

The combination of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone is moving into the frontline setting for patients with diffuse large B-cell lymphoma.

One of the most promising innovations in the multiple myeloma space has been the development of bispecific antibodies.

Treatment with CD19-/CD22-chimeric antigen T-cell therapy demonstrated durable remissions in children with relapsed or refractory B-acute lymphoblastic leukemia, according to a phase 2 study.

For patients with locally advanced or metastatic urothelial cancer, the FDA has accepted for priority review supplemental biologics license applications for enfortumab vedotin-ejfv and pembrolizumab.

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the findings from the ELAINE-1 trial.

In an interview with Targeted Oncology, Martin Dreyling, MD, discussed the implications of the findings from the TRIANGLE study in patients with mantle cell lymphoma.

Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Data from the phase 3 PEARL study show that durvalumab does not induce statistically significant overall survival in patients with metastatic non–small cell lung cancer.

The GLOW trial of zolbetuximab plus capecitabine and oxaliplatin showed statistically significant progression-free and overall survival rates in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Phase 3 study findings have led to the FDA approval of nadofaragene firadenovec-vncg for a subgroup of patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.

Tisagenlecleucel led to durable efficacy and safety in the real-world setting for patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Findings from 3 studies show that treatment with plinabulin elicits efficacy and reduces the duration of severe neutropenia in patients with non–small cell lung cancer receiving docetaxel.

Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.

A more severe symptom burden was seen in patients with isolated thrombocytopenia vs those with isolated anemia, according to findings from the phase 3 PERSIST-1 and PAC203 trials in myelofibrosis.

Early results from the TROPION-PanTumor01 demonstrate the potential of achieving durable response with datopotamab deruxtecan while maintaining tolerability in patients with hormone receptor-positive or HER2-negative breast cancer.

Laura Fernandes, PhD, Senior Statistical Director of COTA, Inc, gives 4 predictions of upcoming trends that will change how clinical trials are performed.

A safety review committee has approved the Acclaim-1 trial of ozeplasmid plus osimertinib in non–small cell lung cancer to move on to the third cohort of the study.

Treatment with olutasidenib induced durable remissions and a manageable adverse event profile in patients with relapsed/refractory acute myeloid leukemia who harbor IDH1 mutations.

A phase 2b trial of pembrolizumab plus a personalized mRNA vaccine resulted in improved recurrence-free survival in patients with resected high-risk melanoma, the first successful randomized trial of its kind.

Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia.

Florida Cancer Specialists & Research Institute, LLC hematologists and medical oncologists were contributors to several presentations at the San Antonio Breast Cancer Symposium® this past week.

Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.